The present invention provides a compound represented by formula (I) [wherein L represents an oxygen atom or CH.sub.2, E represents a C2-C10 chain hydrocarbon group or the like, R.sup.1 represents a C1-C3 chain hydrocarbon group or the like, R.sup.2 represents a C1-C3 chain hydrocarbon group or the like, and n is 0, 1, 2 or 3.] or its N oxide or agriculturally acceptable salt, which is a compound that have excellent pests controlling effects.

##STR00001##

The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.

The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.

Disclosed herein is a compound of Formula I, wherein R.sub.1 is a branched chain alkyl consisting of 10 to 31 carbons; R.sub.2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L.sub.1 and L.sub.2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X.sub.1 is S or O; R.sub.3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R.sub.4 and R.sub.5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt or solvate thereof.

##STR00001##

Disclosed herein is a compound of Formula I, wherein R.sub.1 is a branched chain alkyl consisting of 10 to 31 carbons; R.sub.2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L.sub.1 and L.sub.2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X.sub.1 is S or O; R.sub.3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R.sub.4 and R.sub.5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt or solvate thereof.

##STR00001##

The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

This disclosure relates to a composition and application thereof in antitumor drugs. The composition is prepared from a platinum-based antitumor compound and a novel compound, wherein the novel compound is sodium(S)-2-(dithiocarboxylate ((2S, 3R, 4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-4-(methylthio)butyrate. The novel compound in the composition could effectively chelate the platinum-based antitumor compound and reduce the various adverse effects exhibited by the platinum-based compound. The dosage of the platinum-based antitumor compound can thus be increased, and the antitumor effect can be optimized. The novel compound itself is low-toxic and it has low chelating activities with essential metals in the human body; it would not impose significant adverse effects on the human body at given doses. The composition and its application as an antitumor drug provided by the present disclosure overcome some technical drawbacks of platinum-based antitumor drugs of the prior art, namely severe adverse effects and the development of drug resistance during administration.

This disclosure relates to a composition and application thereof in antitumor drugs. The composition is prepared from a platinum-based antitumor compound and a novel compound, wherein the novel compound is sodium(S)-2-(dithiocarboxylate ((2S, 3R, 4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-4-(methylthio)butyrate. The novel compound in the composition could effectively chelate the platinum-based antitumor compound and reduce the various adverse effects exhibited by the platinum-based compound. The dosage of the platinum-based antitumor compound can thus be increased, and the antitumor effect can be optimized. The novel compound itself is low-toxic and it has low chelating activities with essential metals in the human body; it would not impose significant adverse effects on the human body at given doses. The composition and its application as an antitumor drug provided by the present disclosure overcome some technical drawbacks of platinum-based antitumor drugs of the prior art, namely severe adverse effects and the development of drug resistance during administration.

What is described is a compound of formula I

##STR00001##

consisting of a compound in which R.sub.1 is a branched chain alkyl consisting of 10 to 31 carbons; R.sub.2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons; L.sub.1 and L.sub.2 are the same or different, each a linear alkylene or alkenylene consisting of 2 to 20 carbons; X.sub.1 is S or O; R.sub.3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R.sub.4 and R.sub.5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.